Longboard Pharmaceuticals (LBPH) Stock Forecast, Price Target & Predictions
LBPH Stock Forecast
Longboard Pharmaceuticals stock forecast is as follows: an average price target of $61.00 (represents a 2.52% upside from LBPH’s last price of $59.50) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.
LBPH Price Target
The average price target for Longboard Pharmaceuticals (LBPH) is $61.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $16.00. This represents a potential 2.52% upside from LBPH's last price of $59.50.
LBPH Analyst Ratings
According to 6 Wall Street analysts, Longboard Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for LBPH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 4 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Longboard Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Kalpit Patel | B.Riley Financial | $60.00 | $58.83 | 2.00% | 0.84% |
| Sep 18, 2024 | Patrick Trucchio | H.C. Wainwright | $80.00 | $27.58 | 190.07% | 34.45% |
| Sep 10, 2024 | Joon Lee | Truist Financial | $60.00 | $34.51 | 73.86% | 0.84% |
| Sep 06, 2024 | Joel Beatty | Robert W. Baird | $60.00 | $33.89 | 77.04% | 0.84% |
| Jul 01, 2024 | Josh Schimmer | Cantor Fitzgerald | $90.00 | $28.76 | 212.93% | 51.26% |
| Jun 10, 2024 | Kalpit Patel | B.Riley Financial | $36.00 | $18.11 | 98.79% | -39.50% |
| Apr 30, 2024 | Joel Beatty | Robert W. Baird | $36.00 | $21.30 | 69.01% | -39.50% |
| Nov 11, 2022 | - | Guggenheim | $16.00 | $4.60 | 247.83% | -73.11% |
The latest Longboard Pharmaceuticals stock forecast, released on Oct 14, 2024 by Kalpit Patel from B.Riley Financial, set a price target of $60.00, which represents a 2.00% increase from the stock price at the time of the forecast ($58.83), and a 0.84% increase from LBPH last price ($59.50).
Longboard Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 4 | 7 |
| Avg Price Target | $60.00 | $65.00 | $60.29 |
| Last Closing Price | $59.50 | $59.50 | $59.50 |
| Upside/Downside | 0.84% | 9.24% | 1.33% |
In the current month, the average price target of Longboard Pharmaceuticals stock is $60.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 0.84% increase as opposed to Longboard Pharmaceuticals's last price of $59.50. This month's average price target is down -7.69% compared to last quarter, and down -0.48% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | H.C. Wainwright | Buy | Neutral | Downgrade |
| Oct 14, 2024 | Wedbush | Outperform | Neutral | Downgrade |
| Oct 14, 2024 | B. Riley | Buy | Neutral | Downgrade |
| Oct 14, 2024 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 05, 2024 | B. Riley | Buy | Buy | Hold |
| Jul 02, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 01, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jun 11, 2024 | Citigroup | Buy | Buy | Hold |
| May 03, 2024 | Wedbush | Outperform | Outperform | Hold |
Longboard Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company Downgrade its LBPH rating from "Buy" to "Neutral".
Longboard Pharmaceuticals Financial Forecast
Longboard Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | $3.00M | - |
| High Forecast | - | - | - | - | - | $3.00M | - |
| Low Forecast | - | - | - | - | - | $3.00M | - |
| # Analysts | - | - | - | - | - | 5 | - |
| Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LBPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Longboard Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict LBPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Longboard Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Longboard Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-27.29M | $-26.67M | $-26.91M | $-25.97M | $-24.11M | $-22.49M | $-17.13M |
| High Forecast | $-27.29M | $-26.67M | $-26.91M | $-25.97M | $-24.11M | $-20.97M | $-17.13M |
| Low Forecast | $-27.29M | $-26.67M | $-26.91M | $-25.97M | $-24.11M | $-23.26M | $-17.13M |
| Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LBPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Longboard Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LBPH last annual SG&A of $NaN (undefined).
Longboard Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.70 | $-0.69 | $-0.69 | $-0.67 | $-0.62 | $-0.58 | $-0.44 |
| High Forecast | $-0.70 | $-0.69 | $-0.69 | $-0.67 | $-0.62 | $-0.54 | $-0.44 |
| Low Forecast | $-0.70 | $-0.69 | $-0.69 | $-0.67 | $-0.62 | $-0.60 | $-0.44 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Longboard Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LBPH previous annual EPS of $NaN (undefined).
Longboard Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.52 | $5.50 | 957.69% | Buy |
| HOWL | Werewolf Therapeutics | $2.26 | $12.00 | 430.97% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| TIL | Instil Bio | $27.63 | $78.25 | 183.21% | Hold |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
| CELC | Celcuity | $15.36 | $31.50 | 105.08% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| LBPH | Longboard Pharmaceuticals | $59.50 | $61.00 | 2.52% | Hold |
| IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
LBPH Forecast FAQ
Is Longboard Pharmaceuticals a good buy?
No, according to 6 Wall Street analysts, Longboard Pharmaceuticals (LBPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of LBPH's total ratings.
What is LBPH's price target?
Longboard Pharmaceuticals (LBPH) average price target is $61 with a range of $16 to $90, implying a 2.52% from its last price of $59.5. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Longboard Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for LBPH stock, the company can go up by 2.52% (from the last price of $59.5 to the average price target of $61), up by 51.26% based on the highest stock price target, and down by -73.11% based on the lowest stock price target.
Can Longboard Pharmaceuticals stock reach $90?
LBPH's average twelve months analyst stock price target of $61 does not support the claim that Longboard Pharmaceuticals can reach $90 in the near future.
What is Longboard Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $60 price target for Longboard Pharmaceuticals (LBPH) this month, up 0.84% from its last price of $59.5. Compared to the last 3 and 12 months, the average price target increased by 9.24% and increased by 1.33%, respectively.
What are Longboard Pharmaceuticals's analysts' financial forecasts?
Longboard Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3M (high $3M, low $3M), average EBITDA is $0 (high $0, low $0), average net income is $-63.731M (high $-62.205M, low $-64.493M), average SG&A $0 (high $0, low $0), and average EPS is $-1.639 (high $-1.6, low $-1.659). LBPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-107M (high $-107M, low $-107M), average SG&A $0 (high $0, low $0), and average EPS is $-2.748 (high $-2.748, low $-2.748).